Latest news with #WendyRyan
Yahoo
21-05-2025
- Business
- Yahoo
Verona Pharma Announces June 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company') announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, For further information please contact: Verona Pharma plc Tel: +1-844-341-9901 Victoria Stewart, Senior Director of Investor Relations and Communications IR@ Argot PartnersUS Investor Enquiries Tel: +1-212-600-1902verona@ Ten Bridge CommunicationsInternational / US Media Enquiries Tel: +1-781-316-4424tbcverona@ Wendy Ryan About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Verona Pharma Announces June 2025 Investor Conference Participation
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company') announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, For further information please contact: Verona Pharma plc Tel: +1-844-341-9901 Victoria Stewart, Senior Director of Investor Relations and Communications IR@ Argot PartnersUS Investor Enquiries Tel: +1-212-600-1902verona@ Ten Bridge CommunicationsInternational / US Media Enquiries Tel: +1-781-316-4424tbcverona@ Wendy Ryan About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre® (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-04-2025
- Business
- Yahoo
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona Pharma' or the 'Company') announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States +1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, and the audio replay will be available for 90 days. For further information please contact: Verona Pharma plc Tel: +1-844-341-9901 Victoria Stewart, Senior Director of Investor Relations and Communications IR@ Argot PartnersUS Investor Enquiries Tel: +1-212-600-1902verona@ Ten Bridge CommunicationsInternational / US Media Enquiries Tel: +1-781-316-4424tbcverona@ Wendy Ryan About Verona Pharma Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit in to access your portfolio
